Potential role of sorafenib in the treatment of acute myeloid leukemia

References

• Jabbour E J, Estey E, Kantarjian H M. Adult acute myeloid leukemia. Mayo Clin Proc 2006; 81: 247–260
   PubMed Web of Science ®Google Scholar
• Llovet J M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390
   PubMed Web of Science ®Google Scholar
• Ricciardi M R, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005; 19: 1543–1549
   PubMed Web of Science ®Google Scholar
• Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res 2003; 9: 535–550
   PubMed Web of Science ®Google Scholar
• Doepfner K T, Boller D, Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 2007; 63: 215–230
   PubMed Web of Science ®Google Scholar
• Milella M, Kornblau S M, Estrov Z, Carter B Z, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851–859
   PubMed Web of Science ®Google Scholar
• Milella M, Estrov Z, Kornblau S M, Carter B Z, Konopleva M, Tari A, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99: 3461–3464
   PubMed Web of Science ®Google Scholar
• Milella M, Konopleva M, Precupanu C M, Tabe Y, Ricciardi M R, Gregorj C, et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 2007; 109: 2121–2129
   PubMed Web of Science ®Google Scholar
• Kornblau S M, Womble M, Qiu Y H, Jackson C E, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358–2365
   PubMed Web of Science ®Google Scholar
• Gilliland D G, Griffin J D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542
   PubMed Web of Science ®Google Scholar
• Drexler H G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588–599
   PubMed Web of Science ®Google Scholar
• Lyman S D. Biologic effects and potential clinical applications of FLT3 ligand. Curr Opin Hematol 1998; 5: 192–196
   PubMedGoogle Scholar
• Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91: 459–463
   PubMed Web of Science ®Google Scholar
• Kelly L M, Yu J C, Boulton C L, Apatira M, Li J, Sullivan C M, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421–432
   PubMed Web of Science ®Google Scholar
• Dosil M, Wang S, Lemischka I R. Mitogenic signalling and substrate specificity of the Flk2/FLT3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993; 13: 6572–6585
   PubMed Web of Science ®Google Scholar
• Lisovsky M, Braun S E, Ge Y, Takahira H, Lu L, Savchenko V G, et al. FLT3-ligand production by human bone marrow stromal cells. Leukemia 1996; 10: 1012–1018
   PubMed Web of Science ®Google Scholar
• Lyman S D, Seaberg M, Hanna R, Zappone J, Brasel K, Abkowitz J L, et al. Plasma/serum levels of FLT3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 1995; 86: 4091–4096
   PubMed Web of Science ®Google Scholar
• Martelli A M, Tazzari P L, Evangelisti C, Chiarini F, Blalock W L, Billi A M, et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14: 2009–2023
   PubMed Web of Science ®Google Scholar
• Zeng Z, Sarbassov dos D, Samudio I J, Yee K W, Munsell M F, Ellen Jackson C, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509–3512
   PubMed Web of Science ®Google Scholar
• Bromberg J F, Wrzeszczynska M H, Devgan G, Zhao Y, Pestell R G, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98: 295–303
   PubMed Web of Science ®Google Scholar
• Ning Z Q, Li J, Arceci R J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001; 97: 3559–3567
   PubMed Web of Science ®Google Scholar
• Nakao M, Janssen J W, Erz D, Seriu T, Bartram C R. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia 2000; 14: 522–524
   PubMed Web of Science ®Google Scholar
• Carow C E, Kim E, Hawkins A L, Webb H D, Griffin C A, Jabs E W, et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12–>q13. Cytogenet Cell Genet 1995; 70: 255–257
   PubMedGoogle Scholar
• Karsunky H, Merad M, Cozzio A, Weissman I L, Manz M G. FLT3 ligand regulates dendritic cell development from FLT3+ lymphoid and myeloid-committed progenitors to FLT3+ dendritic cells in vivo. J Exp Med 2003; 198: 305–313
   PubMed Web of Science ®Google Scholar
• Kusadasi N, Koevoet J L, van Soest P L, Ploemacher R E. Stromal support augments extended long-term ex vivo expansion of hemopoietic progenitor cells. Leukemia 2001; 15: 1347–1358
   PubMed Web of Science ®Google Scholar
• McKenna H J, Stocking K L, Miller R E, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking FLT3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489–3497
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin J D, Moore K A, Boast S, Goff S P, Lemischka I R. Targeted disruption of the flk2/FLT3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147–161
   PubMed Web of Science ®Google Scholar
• Zheng R, Friedman A D, Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood 2002; 100: 4154–4161
   PubMed Web of Science ®Google Scholar
• Veiby O P, Jacobsen F W, Cui L, Lyman S D, Jacobsen S E. The FLT3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol 1996; 157: 2953–2960
   PubMed Web of Science ®Google Scholar
• Rosnet O, Buhring H J, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238–248
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335
   PubMed Web of Science ®Google Scholar
• Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004; 13: 169–178
   PubMed Web of Science ®Google Scholar
• Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, et al. Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood, in press
   Google Scholar
• Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66
   PubMed Web of Science ®Google Scholar
• Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and MDS among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605–1609
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907–3914
   PubMed Web of Science ®Google Scholar
• Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000; 108: 322–330
   PubMed Web of Science ®Google Scholar
• Tse K F, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766–1776
   PubMed Web of Science ®Google Scholar
• Radomska H S, Huettner C S, Zhang P, Cheng T, Scadden D T, Tenen D G. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301–4314
   PubMed Web of Science ®Google Scholar
• Ross S E, Radomska H S, Wu B, Zhang P, Winnay J N, Bajnok L, et al. Phosphorylation of C/EBP alpha inhibits granulopoiesis. Mol Cell Biol 2004; 24: 675–686
   PubMed Web of Science ®Google Scholar
• Wang X, Scott E, Sawyers C L, Friedman A D. C/EBP alpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94: 560–571
   PubMed Web of Science ®Google Scholar
• Pabst T, Mueller B U, Zhang P, Radomska H S, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263–270
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien D S. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8: 2255–2257
   PubMed Web of Science ®Google Scholar
• Wilhelm S M, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109
   PubMed Web of Science ®Google Scholar
• Druker B J. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003; 4: 963–971
   PubMed Web of Science ®Google Scholar
• Lyons J F, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8: 219–225
   PubMed Web of Science ®Google Scholar
• Kang B, Hao C, Wang H, Zhang J, Xing R, Shao J, et al. Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res 2008; 7: 3507–3515
   PubMed Web of Science ®Google Scholar
• Steelman L S, Stadelman K M, Chappell W H, Horn S, Basecke J, Cervello M, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008; 12: 1139–1165
   PubMed Web of Science ®Google Scholar
• Sharma A, Trivedi N R, Zimmerman M A, Tuveson D A, Smith C D, Robertson G P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65: 2412–2421
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851–11858
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R A, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835–844
   PubMed Web of Science ®Google Scholar
• Cohen H T, McGovern F J. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–2490
   PubMed Web of Science ®Google Scholar
• Ratain M J, Eisen T, Stadler W M, Flaherty K T, Kaye S B, Rosner G L, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–2512
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–134
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi Y X, Harris D, Small D, Ling X, et al. Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia. Blood 2006; 108
   Google Scholar
• Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21: 439–445
   PubMed Web of Science ®Google Scholar
• Baines P, Fisher J, Truran L, Davies E, Hallett M, Hoy T, et al. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol 2000; 64: 211–218
   PubMed Web of Science ®Google Scholar
• James J A, Smith M A, Court E L, Yip C, Ching Y, Willson C, et al. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J 2003; 4: 427–432
   PubMedGoogle Scholar
• Zhang W, Konopleva M, Ruvolo V R, McQueen T, Evans R L, Bornmann W G, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22: 808–818
   PubMed Web of Science ®Google Scholar
• Adams J M. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003; 17: 2481–2495
   PubMed Web of Science ®Google Scholar
• Bonni A, Brunet A, West A E, Datta S R, Takasu M A, Greenberg M E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358–1362
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek L M, Meng X W, Gores G J, Carter C A, Kaufmann S H, et al. The role of MCL-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24: 6861–6869
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi Y X, McQueen T, Harris D, Ling X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184–198
   PubMed Web of Science ®Google Scholar
• Tong F K, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 2006; 70: 107–114
   PubMed Web of Science ®Google Scholar
• Delmonte J. Update of a phase I study of Sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2007; 110
   Google Scholar
• Safaian N N, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, et al. Sorafenib (Nexavar((R))) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD(+) acute myeloid leukemia. Leuk Res, in press
   Web of Science ®Google Scholar
• Fried W, Chamberlin W, Kedo A, Barone J. Effects of radiation on hematopoietic stroma. Exp Hematol 1976; 4: 310–314
   PubMed Web of Science ®Google Scholar
• Domenech J, Roingeard F, Binet C. The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation. Leuk Lymphoma 1997; 24: 239–256
   PubMed Web of Science ®Google Scholar
• Konopleva M, Konoplev S, Hu W, Zaritskey A Y, Afanasiev B V, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713–1724
   PubMed Web of Science ®Google Scholar
• O'Farrell A M, Foran J M, Fiedler W, Serve H, Paquette R L, Cooper M A, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465–5476
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O G, O'Farrell A M, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993
   PubMed Web of Science ®Google Scholar
• Jarvis W D, Fornari F A, Jr, Tombes R M, Erukulla R K, Bittman R, Schwartz G K, et al. Evidence for involvement of MAP kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 1998; 54: 844–856
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006; 12: 340–344
   PubMed Web of Science ®Google Scholar
• Li L, Piloto O, Kim K T, Ye Z, Nguyen H B, Yu X, et al. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol 2007; 137: 64–75
   PubMed Web of Science ®Google Scholar
• Clark J J, Cools J, Curley D P, Yu J C, Lokker N A, Giese N A, et al. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004; 104: 2867–2872
   PubMed Web of Science ®Google Scholar
• Cools J, Mentens N, Furet P, Fabbro D, Clark J J, Griffin J D, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64: 6385–6349
   PubMed Web of Science ®Google Scholar